Compass Pathways plc and Osmind announced a collaboration on April 21, 2026 to expand the readiness of psychedelic clinics for the delivery of COMP360, Compass’s synthetic psilocybin therapy. The partnership will provide Osmind’s network of more than 1,000 interventional psychiatry practices with guidance on integrating COMP360 into existing clinical workflows.
The collaboration marks a strategic shift for Compass, moving beyond its own clinical trial sites to a network‑based delivery model. By leveraging Osmind’s established infrastructure, Compass aims to accelerate the rollout of its single‑dose treatment across the United States, potentially shortening the time to market and expanding patient access once FDA approval is secured.
COMP360 has received Breakthrough Therapy designation from the FDA for treatment‑resistant depression and is positioned to address a sizable market. The treatment‑resistant depression market was valued at $2.08 billion in 2026 and is projected to reach $2.87 billion by 2033, while the PTSD market is estimated at $18.47 billion in 2024 and could grow to $33.05 billion by 2035.
Compass Pathways reported a net loss of $93.88 million for Q4 2025, compared with $43.33 million a year earlier, and a net loss of $17.9 million for Q1 2025, an improvement from $35.2 million in Q1 2024. The company’s cash reserves stood at $185.9 million as of September 30 2025 and $221.9 million as of June 30 2025, giving it a runway into 2027 and supporting its ongoing capital raises, including a $150 million financing and the exercise of $200 million in warrants.
Dr. Steve Levine, Chief Patient Officer, emphasized Compass’s commitment to responsible delivery, stating, “A core focus for Compass is to ensure that COMP360 can be delivered responsibly, safely, and effectively in the real‑world settings where patients receive care.” Jimmy Qian, Co‑Founder and President of Osmind, noted, “Independent psychiatry practices serve the majority of patients but face operational challenges when adopting innovative treatments.”
The partnership is expected to enhance Compass’s scalability and position it to capture a larger share of the treatment‑resistant depression and PTSD markets once regulatory approval is obtained, reinforcing the company’s strategy to expand beyond its own trial sites.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.